WO2012085888A3 - Polyelectrolyte complex, process for its manufacture and use thereof - Google Patents

Polyelectrolyte complex, process for its manufacture and use thereof Download PDF

Info

Publication number
WO2012085888A3
WO2012085888A3 PCT/IB2011/055928 IB2011055928W WO2012085888A3 WO 2012085888 A3 WO2012085888 A3 WO 2012085888A3 IB 2011055928 W IB2011055928 W IB 2011055928W WO 2012085888 A3 WO2012085888 A3 WO 2012085888A3
Authority
WO
WIPO (PCT)
Prior art keywords
polyelectrolyte complex
present
relates
manufacture
polyelectrolyte
Prior art date
Application number
PCT/IB2011/055928
Other languages
French (fr)
Other versions
WO2012085888A2 (en
Inventor
Marina Inés GIANNOTTI
Fausto Sanz Carrasco
Simon Schwartz Navarro
Original Assignee
Centro De Investigación Biomédica En Red En Bioingeniería, Biomateriales Y Nanomedicina
Fundació Privada Institut De Bioenginyeria De Catalunya
Universitat De Barcelona
Fundació Institut De Recerca Hospital Universitari Vall D'hebron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro De Investigación Biomédica En Red En Bioingeniería, Biomateriales Y Nanomedicina, Fundació Privada Institut De Bioenginyeria De Catalunya, Universitat De Barcelona, Fundació Institut De Recerca Hospital Universitari Vall D'hebron filed Critical Centro De Investigación Biomédica En Red En Bioingeniería, Biomateriales Y Nanomedicina
Publication of WO2012085888A2 publication Critical patent/WO2012085888A2/en
Publication of WO2012085888A3 publication Critical patent/WO2012085888A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a polyelectrolyte complex comprising a protein, a chitosan derivative and tripolyphosphate polyanion with an average particle diameter size lower than 200 nm. The present invention also relates to a process for manufacturing said polyelectrolyte complex. The present invention further relates to the use of said polyelectrolyte complex as a carrier and delivery sustem for proteins, in particular to be delivered to lysosomes and more particularly in endothelial cells. The present invention additionally relates to use of said polyelectrolyte complex for the manufacture of a medicament for treating a lysosomal disease, in particular Fabry disease.
PCT/IB2011/055928 2010-12-23 2011-12-23 Polyelectrolyte complex, process for its manufacture and use thereof WO2012085888A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201031933 2010-12-23
ESP201031933 2010-12-23

Publications (2)

Publication Number Publication Date
WO2012085888A2 WO2012085888A2 (en) 2012-06-28
WO2012085888A3 true WO2012085888A3 (en) 2012-10-11

Family

ID=45558346

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2011/055928 WO2012085888A2 (en) 2010-12-23 2011-12-23 Polyelectrolyte complex, process for its manufacture and use thereof

Country Status (1)

Country Link
WO (1) WO2012085888A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114835923A (en) * 2015-08-13 2022-08-02 约翰霍普金斯大学 Method for preparing polyelectrolyte complex nanoparticles
EP4093437A2 (en) * 2020-01-22 2022-11-30 Engene, Inc. Localized expression of therapeutic nucleic acids in lung epithelial cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AMIDI M ET AL: "Chitosan-based delivery systems for protein therapeutics and antigens", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER BV, AMSTERDAM, NL, vol. 62, no. 1, 31 January 2010 (2010-01-31), pages 59 - 82, XP026877915, ISSN: 0169-409X, [retrieved on 20091116] *
CSABA N ET AL: "Ionically crosslinked chitosan/tripolyphosphate nanoparticles for oligonucleotide and plasmid DNA delivery", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, vol. 382, no. 1-2, 1 December 2009 (2009-12-01), pages 205 - 214, XP026708561, ISSN: 0378-5173, [retrieved on 20090804], DOI: 10.1016/J.IJPHARM.2009.07.028 *
JINTAPATTANAKIT ET AL: "Peroral delivery of insulin using chitosan derivatives: A comparative study of polyelectrolyte nanocomplexes and nanoparticles", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, vol. 3427, 8, no. 1-2, 17 August 2007 (2007-08-17), pages 240 - 249, XP022206329, ISSN: 0378-5173, DOI: 10.1016/J.IJPHARM.2007.05.015 *

Also Published As

Publication number Publication date
WO2012085888A2 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
WO2011119995A3 (en) Formulations and methods of use
CA2867888C (en) Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo
WO2009114614A3 (en) Compositions and methods for controlled delivery of inhibitory ribonucleic acids
MX342439B (en) Methods to produce polymer nanoparticles and formulations of active ingredients.
WO2011129549A3 (en) Anticancer drug delivery system using ph-sensitive metal nanoparticles
WO2011084808A3 (en) Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
WO2011141705A8 (en) Novel cationic lipids and methods of use thereof
WO2011100425A3 (en) Methods and compositions for wound healing
WO2010048536A3 (en) Processes for preparing lipids
WO2015152693A3 (en) Novel double-stranded oligo rna and pharmaceutical composition comprising same for preventing or treating fibrosis or respiratory diseases
WO2011143201A3 (en) Ratiometric combinatorial drug delivery
WO2012101639A3 (en) Nanoparticles based for dermal and systemic delivery of drugs
WO2010144789A3 (en) Diketopiperazine microparticles with defined specific surface areas
WO2011084518A3 (en) Therapeutic polymeric nanoparticles comprising corticosteroids and methods of making and using same
WO2009097508A3 (en) Methods and compositions for wound healing
WO2012040623A3 (en) Nanostructured gels capable of controlled release of encapsulated agents
WO2009135853A3 (en) Encapsulation of biologically active agents
WO2008001240A3 (en) Transdermal delivery of oleocanthal for relief of inflammation
WO2010000877A3 (en) Formulation with irritation reducing action comprising bisabolol and [6]-paradol
WO2008093195A3 (en) Chitosan-based colloidal particles for rna delivery
WO2015048498A3 (en) Carrier-free biologically-active protein nanostructures
WO2010129819A3 (en) Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
WO2012104275A3 (en) Nanoparticles delivery systems, preparation and uses thereof
WO2012056321A3 (en) Bulk enteric capsule shells
WO2014044461A3 (en) Stabilization of capsule systems in laundry detergents and other cleaning products

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11813902

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11813902

Country of ref document: EP

Kind code of ref document: A2